Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01070823 · ClinicalTrials.gov registry record
JC-Virus (JCV) Antibody Program
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 1,096
- Enrollment target
NCT01070823 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 1,096 participants.
The verdict
NCT01070823 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 1,096 participants
- Enrollment target
Study Summary
The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment. Secondary objectives are to analytically validate the anti-JCV antibody assay in a plasma matrix and to determine changes in anti-JCV antibody status over time.
Interventions
- DRUG Tysabri® (natalizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,096 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01070823
The ClinicalTrials.gov registry entry for NCT01070823 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,096 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tysabri® (natalizumab) is the first listed.
NCT01070823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01070823 about?
NCT01070823 is a clinical study titled "JC-Virus (JCV) Antibody Program". The primary objective is to define the prevalence of serum anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving Tysabri® (natalizumab) or being considered for such treatment. Secondary objectives are to analytically validate the anti-JCV antibody assay in a plasma matrix and...
What is the current status of trial NCT01070823?
This trial is currently completed. The enrollment target is 1,096 participants. The study started on 2010-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01070823?
The interventions under investigation include: Tysabri® (natalizumab) (DRUG).
Who is sponsoring clinical trial NCT01070823?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.